186 related articles for article (PubMed ID: 38654290)
21. m
Li W; Liu J; Ma Z; Zhai X; Cheng B; Zhao H
Dis Markers; 2021; 2021():8859590. PubMed ID: 34234878
[TBL] [Abstract][Full Text] [Related]
22. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
23. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on NK cell marker genes to predict prognosis and immunotherapy response in hepatocellular carcinoma.
Yang D; Zhao F; Su Y; Zhou Y; Shen J; Yu B; Zhao K; Ding Y
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10609-10621. PubMed ID: 37296316
[TBL] [Abstract][Full Text] [Related]
24. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma.
Zhou Y; Li X; Long G; Tao Y; Zhou L; Tang J
Front Immunol; 2022; 13():994259. PubMed ID: 36341373
[TBL] [Abstract][Full Text] [Related]
26. A Predictive Model Based on the FBXO Family Reveals the Significance of Cyclin F in Hepatocellular Carcinoma.
Gao D; Li S; Guo H; Liu X; Liu Z; Li L; Bao L; Dang X
Front Biosci (Landmark Ed); 2024 May; 29(5):202. PubMed ID: 38812312
[TBL] [Abstract][Full Text] [Related]
27. Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
Fang G; Zhang Q; Fan J; Li H; Ding Z; Fu J; Wu Y; Zeng Y; Liu J
BMC Cancer; 2022 Sep; 22(1):999. PubMed ID: 36127654
[TBL] [Abstract][Full Text] [Related]
28. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
[TBL] [Abstract][Full Text] [Related]
29. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
[TBL] [Abstract][Full Text] [Related]
30. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
31. A robust nine-gene prognostic signature associated with tumour doubling time for hepatocellular carcinoma.
Huo J; Wu L; Zang Y
Life Sci; 2020 Nov; 260():118396. PubMed ID: 32918973
[TBL] [Abstract][Full Text] [Related]
32. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
33. A stemness-based eleven-gene signature correlates with the clinical outcome of hepatocellular carcinoma.
Hong L; Zhou Y; Xie X; Wu W; Shi C; Lin H; Shi Z
BMC Cancer; 2021 Jun; 21(1):716. PubMed ID: 34147074
[TBL] [Abstract][Full Text] [Related]
34. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
35. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.
Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X
Front Immunol; 2024; 15():1397541. PubMed ID: 38774870
[TBL] [Abstract][Full Text] [Related]
36. Identification of an RNA binding protein-related gene signature in hepatocellular carcinoma patients.
Wang L; Zhou N; Qu J; Jiang M; Zhang X
Mol Med; 2020 Dec; 26(1):125. PubMed ID: 33297932
[TBL] [Abstract][Full Text] [Related]
37. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
[TBL] [Abstract][Full Text] [Related]
38. Bioinformatics Analysis of Prognostic Tumor Microenvironment-Related Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Tian Z; Wang Z; Chen Y; Qu S; Liu C; Chen F; Ma L; Zhu J
Med Sci Monit; 2020 Mar; 26():e922159. PubMed ID: 32231177
[TBL] [Abstract][Full Text] [Related]
39. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
[TBL] [Abstract][Full Text] [Related]
40. Identification of SARS-CoV-2 Proteins Binding Human mRNAs As a Novel Signature Predicting Overall Survival in Hepatocellular Carcinoma.
Chen S
DNA Cell Biol; 2021 Feb; 40(2):359-372. PubMed ID: 33290144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]